First diagnostic test for Alzheimer’s, Parkinson’s on the anvilApril 7th, 2008 - 1:40 pm ICT by admin
London, Apr 7 (ANI): A US company has revealed that it plans to launch new blood test that can give an early diagnosis of neurodegenerative disease and distinguish between Parkinsons and Alzheimers disease.
Manufacturer, Oklahoma-based proteomics company, Power3 Medical Products, said it plans to sell the test, NuroPro, which would be the first diagnostic test for neurodegenerative diseases on the market, in Greece by Q3 with further plans for it to go on the US market by late Q3 or Q4.
“There is currently no diagnostic test for any neurodegenerative disease on the market - diagnoses are currently based solely on a clinical diagnosis of symptoms,” BBC quoted Steve Rash, CEO of Power3 Medical Products, as saying.
NuroPro measures the levels of 59 biomarkers or proteins in the blood that could be used to differentiate between Alzheimer’s, Parkinson’s and also Lou Gehrig’s disease.
According to the company, while testing more than 180 patients the test achieved 60-70 pct a success in identifying Alzheimer’s, Parkinson’s or Lou Gehrig’s.
“Whilst the NuroPro test sounds promising, a larger study would need to be carried out before it can be confirmed as being helpful in making the diagnosis of Parkinson’s, said Kieran Breen, director of research at the Parkinson’s Disease Society,
“A blood test could also be particularly useful in monitoring the progression of Parkinson’s and assessing agents or drugs that modify the rate of disease development,” Breen added.
Two clinical validation studies are currently underway at the Cleo Roberts Center of Clinical Research in Arizona, US, and the Research Institute of Thessaly in Greece. (ANI)
Tags: anvil, biomarkers, breen, clinical diagnosis, clinical validation, diagnosis of symptoms, diagnostic test, director of research, gehrig s disease, kieran, lou gehrig, neurodegenerative diseases, new blood, parkinson s disease, parkinsons, power3 medical products, proteomics company, steve rash, thessaly, validation studies